A B S T R A C T
The growing importance of quality of life (QoL) measures in health care is reflected by the increased volume and rigor of published research on this topic. The ability to measure and assess patients' experience of symptoms and functions has transformed the development of disease treatments and interventions. However, QoL remains an under-investigated issue in chronic kidney disease (CKD) and is seldom set as an outcome measure in trials in this population. In this article, we present various challenges in using patient-reported outcome (PRO) end points in CKD trials. We outline the need for additional research to examine more closely patient experiences with specific kidney disease symptoms and conditions, as well as caregiver perspectives of patients' symptom burden and end-of-life experiences. These efforts will better guide the development or enhancement of PRO instruments that can be used in clinical trials to more effectively assess treatment benefit, and improve therapy and care. Better understanding of health-related QoL issues would enable providers to deliver more patient-centered care and improve the overall well-being of patients. Even small improvements in QoL could have a large impact on the population's overall health and disease burden.
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I N T R O D U C T I O N
Patient-reported outcome (PRO) measures of patient symptoms and functioning have gained importance over the past 20 years. Clinicians, researchers and regulators recognize that assessment of PROs can increase our understanding of the effect of therapeutic interventions and improve patient care [1, 2] . PRO is a broad term used to describe data collected directly from the patient without interpretation by clinicians or proxies and includes functional and health status, health-related quality of life (HRQoL) and quality of life (QoL) [3, 4] . There is a wide range of application and use of PROs-from providers utilizing PROs in their clinical practice on various domains covered in PRO instruments, to investigators in academic, research, and industry settings interested in understanding the effect of therapeutic interventions on patients' HRQoL [5] . In randomized controlled trials, PRO measures are being used as clinical end points in patients with symptomatic conditions or conditions that affect daily functioning [6] [7] [8] .
PROs are especially appropriate to help improve care for patients with chronic conditions, such as chronic kidney disease (CKD), indeed because the conditions are chronic. Patients can expect to live many years with their diagnosed conditions and efforts are channeled more toward alleviating symptoms, slowing the loss of functional nephrons and delaying the onset of kidney failure, rather than achieving a cure [9] . Given the potential utility of PROs in chronic care, the Centers for Medicare & Medicaid Services (CMS) has mandated periodic evaluation of QoL for dialysis patients; consequently, the nephrology community is determining how to incorporate PRO measurement into routine patient care [2] .
However, despite all the attention given to PRO in the CKD population, QoL is under-investigated in clinical trials and is seldom set as an outcome measure-especially as the primary end point. The reasons why QoL is underutilized in CKD trials has not been well examined. In doing so, a number Nephrol Dial Transplant (2017) 32: ii47-ii52 doi: 10.1093/ndt/gfw399 Advance Access publication 16 February 2017 of germane questions should be answered. Are there unique challenges in the CKD patient population? Are there issues in assessing HRQoL at end of life? Are clinical end points in CKD trials difficult to define? Are some symptom assessment methods inadequate? Are certain disease burdens experienced by CKD patients not captured in existing PRO instruments? In this review, we describe various challenges that might explain why QoL is under-investigated in CKD trials. Overcoming these challenges will allow us to more effectively assess QoL and improve the QoL of the CKD patient population.
CKD is a health problem affecting 8-16% of the global population [10] and 14% of the US population [11] . It is a heterogeneous condition, with many different causes, manifestations, comorbid conditions and factors affecting prognosis [12] . CKDs is defined as the presence of kidney damage [glomerular filtration rate (GFR) <60 mL/min/1.73 m 2 for 3 months] [13] . Most CKD progresses slowly, and with compromised kidney function, comorbidities can gradually develop, e.g. anemia, hypertension inflammation, malnutrition, and metabolic and mineral-bone disorders [13] . In category G5, CKD may progress to end-stage renal disease (ESRD) and treatment options include renal replacement therapy-either dialysis or transplantation-and conservative care [14, 15] .
A major challenge in conducting CKD trials is the heterogeneity of CKD. CKD affects a wide ranging patient populationfrom young individuals with genetic or glomerular diseases to older patients with diseases such as high blood pressure and diabetes that affect the kidney. Consequently, QoL and PRO are not interchangeable in these populations. Although many of the concepts related to PRO instruments apply to both adult and pediatric populations, the challenge is how to capture responses in children who cannot respond for themselves [16] . In such a setting, it may be reasonable to use measurement on the basis of a report of observable signs, events or behaviors related to a patient's health condition by someone other than the patient or a health professional. For example, in glomerular diseases and nephrotic syndromes, parents and caregivers can observe the presence of edema in a child. What is unclear is whether the observed changes in edema affect how the child feels or functions. In this case, the observer report of edema could be supplemented by an observation-based instrument assessing the effect of the edema on daily life functioning [16] .
At the other end of the age spectrum, older adults account for a significant proportion of the overall population with CKD [11, 17, 18] . The majority of older adults often have multiple, complex comorbid conditions (e.g. heart failure, atherosclerosis, high blood pressure, diabetes mellitus, and cognitive deterioration) that may affect the CKD prognosis [17, [19] [20] [21] . In trials where the primary goal is to evaluate the efficacy or effectiveness of interventions, treatment effects are detected and interpreted more easily in homogenous populations [17] . With older adults (70 years), for example, one study showed no significant improvements with therapy due to small sample size, the result of poor recruitment and early study termination [22] . Hence, older adults with complex comorbidity are frequently excluded from trials and not subjected to rigorous testing or evaluations [17, [23] [24] [25] [26] .
Furthermore, advanced CKD patient participation in endof-life research is problematic due to the difficulty of prospectively identifying patients in the dying phase and the challenges inherent in studying a subjective experience in individuals with progressive physical and cognitive impairment [27, 28] . In order to collect useful PRO data regarding the quality of their terminal care, patient subjects must have some awareness of terminality and a willingness or capability to discuss their preferences and goals (e.g. spiritual peace, mending relationships with family and friends, goals of comfort, preferences in intensity of treatments, and place of death) [29] .
Hence, despite the potential limitations of proxy reports of patient experiences [30, 31] , investigators need to rely on retrospective reports from non-patient informants. Indeed, the perspectives of caregivers are of clinical importance, given that they are corecipients of palliative and end-of-life care, are decision makers when patients are incapable, and bear the burden of illness and grief [29] . Inclusion of their experiences in clinical trials to determine whether and how caregivers' perspectives reflect or are unique from those of patients at end-of-life is a key topic for further investigation.
C H A L L E N G E S I N D E F I N I N G C L I N I C A L E N D P O I N T S

Disease-based outcomes as primary end points
Another challenge is defining clinical end points (PRO and non-PRO assessments) in CKD trials [32] . Clinical end point is defined as a characteristic or variable that reflects how a patient feels, functions or survives [33] . In earlier stages of CKD, it is difficult to define suitable end points for clinical trials due to lack of specific symptoms prior to the stage of kidney failure. And with slow progression of CKD, existing non-PRO clinical end points for CKD (e.g. progression to ESRD or kidney failure) may not be reached for decades [34] . Also, the known biomarkers for the clinical end points (i.e. serum creatinine, GFR and proteinuria) require long durations of follow-up and large sample sizes in clinical trials. For example, Levey et al. retrospectively analyzed the Modification of Diet in Renal Disease (MDRD) Study which hypothesized that protein restriction slows the progression of chronic renal disease and posited that the original study outcome was inconclusive because the GFR decline was too slow and the duration of follow-up was too short to determine an effect of the dietary intervention on long-term GFR decline [35] . Given the slow mean rate of GRF decline observed in the MDRD Study, Levey et al. estimated an additional three or more years of follow-up was needed to detect a difference from baseline to the end of the MDRD Study [35] .
Hence, it is challenging to develop therapeutic interventions because the beneficial effects of treatment measured by biomarkers or non-PRO end points are not expected to manifest ii48 K. Chong and M. Unruh
for many years. In some cases, biomarkers can be not predictive. For example, in autosomal dominant polycystic kidney disease (ADPKD), kidney function declines gradually over decades and leads to ESRD in a significant proportion of patients [34] . Despite progressive growth of the kidney cysts, the early course of ADPKD is actually characterized by hyperfiltration and relatively normal GFR for many decades [36] . This makes GFR an insensitive marker of underlying renal parenchymal damage in ADPKD [34] . The role of a PRO end point in clinical trials (i.e. a primary, key secondary or exploratory end point) can be planned and illustrated using an end point model-a diagram of the hierarchy of relationships among all end points (both PRO and non-PRO), that corresponds to the clinical trial's objectives, design and data analysis plan [3] . Figures 1 and 2 illustrate examples of end point models. Figure 1 shows treatment of Disease X with a physiologic measure as the primary end point (disease-based outcome), and PRO symptom assessment (non-disease-based outcome) as secondary end points intended to support an indication for the treatment of Disease X [3] .
In this model, the clinical trial would need to reach the physiologic end point before secondary end points could be achieved [3] . Because most CKD progress slowly, PRO assessments in the secondary end point may never be reached during the trial timeframe. This limitation is typical of nephrology trials that focus on disease-based outcome measures; which drive evidence-based practice guidelines and current standards of nephrology care [17, 18, 37] . Moreover, such disease-based outcome studies typically do not address outcomes that matter most to individual patients, such as overall symptom burden and HRQoL [38] . This is especially true for older adults with CKD who often have a significant functional impairment and other comorbidities that are associated with but not necessarily caused by their CKD [39, 40] . These coexisting comorbidities and functional impairment may critically influence treatment options and alter the benefit and harm of disease-related approaches to CKD management [17] . O'Hare et al. point out that the high prevalence of other health conditions in older adults with CKD may often limit the relevance of a disease-specific approach to research and suggest that interventions targeted more broadly at maintaining health may make more sense than those narrowly focused on preserving kidney function [17] .
Non-disease-based outcomes as primary end points
Unlike outcomes with physiologic or biochemical end points that do not directly influence how patients feel, non-disease-based outcomes, such as symptom burden and HRQoL, are outcomes that are directly relevant to patients [41] . Patients with CKD experience an array of symptoms, e.g. fatigue, pain, depression, sleep disturbances, cognitive difficulties, and sexual dysfunction. Many studies confirm the negative impact of these symptoms on HRQoL and the continuous deterioration of HRQoL with more advanced disease stages [42] [43] [44] . In a cross-sectional design study with 535 patients in CKD stages 2-5, all HRQoL dimensions deteriorated significantly with increasing CKD stages, with the lowest scores in CKD stage 5 [42] . This study revealed that even in CKD stages 2-3, HRQoL decreased significantly compared with matched controls. In a larger scale prospective study cohort of 1186 CKD patients, the majority of the scores declined across the three stages of CKD (3) (4) (5) , exceeding the minimally clinically important difference on the scale [44] . In the treatment of ESRD patients on dialysis, HRQoL is a critical issue because treatment goals are to extend life and also to control a variety of symptoms and comorbidities. A survey of hemodialysis patients confirms the importance placed on absence of adverse effects of treatment, and maintenance of good physical function and state [45] .
Treatment of symptoms associated with CKD can be conceptualized in a trial using an end point model as shown in Figure 2 . In Figure 2 , PRO symptom assessment is the primary clinical trial end point intended to support an indication for the treatment of symptoms associated with Disease Y, and the physical performance and limitation measures are the key secondary end points [3] .
For advanced CKD patients facing imminent death, greater importance may be placed on psychosocial (e.g. spirituality) than physical issues [46] . Quality end-of-life care should encompass any combination of pain and symptom management, psychological and spiritual care, and social support when there are no longer any curative treatment options [47] .
C H A L L E N G E S I N A S S E S S I N G S Y M P T O M S
One frequent and troubling symptom for patients on hemodialysis is fatigue [48] , which is often unrecognized and undertreated [49] . In a study that used ecological momentary assessment, hemodialysis patients experienced daily and diurnal variation in fatigue, sleepiness and exhaustion [50] . The variability in these symptoms may contribute to poor symptom awareness by providers and greater misclassification bias of fatigue-related symptoms in clinical studies [50] . Inadequate assessment methods, lack of provider awareness and the complex pathogenesis of fatigue may have thwarted the development of effective interventions to treat it [49] .
Edema, experienced by patients with nephrotic syndrome, is another symptom that is challenging to measure and assess. While a relatively large body of literature mostly addresses its pathophysiology, discussion of its impact as experienced by the patient is sorely lacking [51] . Nephrotic syndrome is a specific renal condition where progression to kidney failure occurs in 20-90% of afflicted adults [2] . It is a condition that may relapse and remit and thus change over time independent of the therapeutic approach [2] . Current treatment, typically assessed by reduction in proteinuria, reduces the risk of kidney failure; however, the time to reach important clinical end points is often prolonged and many patients continue to experience significant morbidity related to nephrotic syndrome. With no available measure to capture PROs important to patients with nephrotic syndrome, Perrone et al. justify the exploration of PROs as clinical end points to further guide the development of potentially impactful therapies for nephrotic syndrome [2] .
C H A L L E N G E S I N P R O M E A S U R E S A N D I N S T R U M E N T S
Over the past two decades, there has been substantial progress in the development of PRO tools that have been used to measure the desired outcomes [52, 53] . HRQoL tools encompass a wide range of domains (including social, psychological, therapeutic and physical domains), which are readily available for use in general populations [29, 53] . Various literature reviews have catalogued commonly used instruments with descriptions for their use, as well as made assessments of the tools' content, comprehensiveness, reliability and validity [52, 53] . The optimal QoL instrument is one that captures the impact of disease, injury and/or treatment on the physical, mental and social dimensions of well-being or HRQoL. Generic tools, such as the 36-Item Short Form Survey (SF-36), can compare different populations; but these instruments may not detect small, clinically important changes in specific chronic disease populations, e.g. ESRD patients. The Kidney Disease Quality of Life (KDQOL) survey is the most widely used disease-targeted HRQoL instrument among dialysis-dependent patients [53, 54] . Disease-targeted instruments are potentially more sensitive to the characteristics of specific populations and more responsive to change over time, but in exchange, they may not be applicable to other disease populations. They are particularly important in clinical trials when the difference between study arms may be limited to a small number of dimensions of HRQoL [52] . In clinical trials, a PRO instrument can be used to measure the effect of a therapeutic intervention on one or more concepts (i.e. a symptom or group of symptoms being measured, effects on a particular function or group of functions, or a group of symptoms or functions shown to measure the severity of a health condition) [3] .
However, despite various PRO tools available to the nephrology community, including tools that measure HRQoL at end of life [29, 29, 53, 55] , they do not capture certain specific kidney disease symptoms experienced by patients. New PRO tools or enhancement of existing PRO tools are warranted in some conditions (e.g. glomerular disease, nephrotic syndrome, anemia, and ADPKD) to more effectively assess treatment effects in trials [2] .
An emerging tool, the National Institutes of Health-funded Patient Reported Outcomes Measurement Information System (PROMIS), catalogs and makes available for use a variety of validated, efficient and responsive PRO measures [56, 57] . This system is intended to be a collection of highly reliable, precise measures of patient-reported health status for physical, mental and social well-being. PROMIS measures have been standardized to include common domains and metrics across conditions, allowing for comparisons across domains and diseases [56, 57] . However, given the focus of PROMIS on generic measures of symptoms common to many diseases (e.g. pain) and broad areas of function (e.g. physical and cognitive functions) rather than measures addressing a comprehensive set of disease-specific symptoms, PROMIS tools have not been favorably reviewed by the Food and Drug Administration [58] .
Ware et al. recently conducted a study to evaluate the convergent and discriminant validity of QoL attributions to specific diseases among adults with multiple chronic conditions (MCCs) within eight pre-identified conditions, which includes CKD [59] . Their study results support aggregating diseasespecific QoL impact rating across conditions to estimate the total MCC burden in QoL terms. The authors conclude that such a global QoL impact measure is a valid addition to the toolkit for monitoring PROs for each of the conditions studied and warrant their use among adults with MCCs. Thus, the pursuit of a summary disease-specific QoL impact score standardized across MCC is recommended [59] .
An innovative method of capturing PROs electronically with electronic medical records (EMRs) has been shown to be an effective way to integrate existing care pathways and to facilitate receiving interventions in a timely manner. Studies showed that this approach improves HRQoL, and incorporating such technology to HRQoL assessment will likely improve patientdoctor communication, lead to more accurate HRQoL and symptom assessment and decrease the patient's burden of responding to conventional HRQoL instruments [50, 60] . Moreover, an alternative to traditional study visits may involve newer modes of communication, in which patient-reported information is collected through text messaging, apps on smartphones and tablets or other home-monitoring devices, which optimizes prospective data collection while minimizing study burden [61] . Simultaneously, the EMR may be used to collect clinical and research data, or collected data may be accessed for subsequent research endeavors [61] . Lastly, computerized adaptive testing (CAT) is becoming increasingly important in the assessment of PRO in the clinical setting. CAT is a simple form of artificial intelligence that selects questions tailored to the respondent to achieve the desired precision so that results can be compared and displayed instantly [62] . Creative and effective use of the EMR has the potential to reduce data collection redundancies and increase research participation by patients, caregivers and clinicians.
C O N C L U S I O N
Although patient-centered care has gained importance, PRO measures of patient symptoms and functions have seldom been used as valid clinical end points in trials in the CKD population.
We have explored some of the challenges as well as opportunities in using PRO end points in CKD trials. Additional research is necessary to examine more closely patient experiences with specific kidney disease symptoms and conditions, as well as caregiver perspectives of patients' symptom burden and end-of-life experiences. These efforts will better guide the development of new PRO instruments or enhancement of existing PRO instruments that can be used in clinical trials to more effectively assess treatment benefit and improve therapy and care. The relevance of these studies should be obvious because these more complex populations consume a large share of healthcare services. Better understanding of HRQoL issues would enable providers to deliver more patientcentered care and improve the overall well-being of patients. Even incremental improvements in QoL could have a large impact on the population's overall health and disease burden.
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